DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,993 filers reported holding DANAHER CORPORATION in Q3 2022. The put-call ratio across all filers is 1.00 and the average weighting 0.7%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $15,673,210 | +13.1% | 63,442 | +9.9% | 0.21% | +17.2% |
Q2 2023 | $13,852,266 | +31.5% | 57,708 | +38.1% | 0.18% | +37.4% |
Q1 2023 | $10,534,661 | +24.1% | 41,801 | +30.6% | 0.13% | +5.6% |
Q4 2022 | $8,488,549 | +12.3% | 31,998 | +9.6% | 0.12% | +2.5% |
Q3 2022 | $7,556,000 | -15.1% | 29,208 | -16.9% | 0.12% | -9.7% |
Q2 2022 | $8,905,000 | +58.4% | 35,131 | +82.3% | 0.13% | +76.3% |
Q1 2022 | $5,621,000 | -63.5% | 19,267 | -59.0% | 0.08% | -62.9% |
Q4 2021 | $15,417,000 | -10.6% | 46,936 | -17.1% | 0.20% | -24.4% |
Q3 2021 | $17,237,000 | +14.1% | 56,616 | +0.5% | 0.27% | +0.7% |
Q2 2021 | $15,113,000 | +37.8% | 56,320 | +15.6% | 0.27% | +24.0% |
Q1 2021 | $10,964,000 | -5.2% | 48,708 | -6.4% | 0.22% | -19.3% |
Q4 2020 | $11,565,000 | +7.2% | 52,064 | +3.9% | 0.27% | -14.1% |
Q3 2020 | $10,790,000 | +21.6% | 50,113 | -0.1% | 0.31% | +9.8% |
Q2 2020 | $8,874,000 | -8.8% | 50,184 | -28.6% | 0.28% | -17.6% |
Q1 2020 | $9,730,000 | -8.6% | 70,305 | +1.3% | 0.35% | +3.0% |
Q4 2019 | $10,647,000 | – | 69,377 | – | 0.34% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
Third Point | 2,450,000 | $607,845,000 | 9.22% |
Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |